

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM363928

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Notice of Release of Security Interest		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A.		11/25/2015	national banking association: UNITED STATES
RECEIVING PARTY DATA			
Name:	US Worldmeds, LLC		
Street Address:	4010 Dupont Circle		
Internal Address:	Suites 574, L-07, L-11, 401 and 409		
City:	Louisville		
State/Country:	KENTUCKY		
Postal Code:	40207		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3871489	REVONTO	
Registration Number:	2973482	APOKYN	
CORRESPONDENCE DATA			
Fax Number:	9192868199		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	919 286-8000		
Email:	PTO_TMconfirmation@mvalaw.com		
Correspondent Name:	MOORE & VAN ALLEN PLLC		
Address Line 1:	3015 CARRINGTON MILL BOULEVARD		
Address Line 2:	SUITE 400		
Address Line 4:	MORRISVILLE, NORTH CAROLINA 27560		
ATTORNEY DOCKET NUMBER:	036251-23		
NAME OF SUBMITTER:	John E. Slaughter		
SIGNATURE:	/John E. Slaughter/		
DATE SIGNED:	11/30/2015		
Total Attachments: 4			
source=Release Patents and TM's 0301#page1.tif			

OP \$65.00 3871489

source=Release Patents and TM's 0301#page2.tif

source=Release Patents and TM's 0301#page3.tif

source=Release Patents and TM's 0301#page4.tif

NOTICE OF RELEASE OF SECURITY INTEREST

This Notice of Release of Security Interest (the "Release") is effective as of November 25, 2015, by **JPMORGAN CHASE BANK, N.A.** (together with its successors, "Secured Party").

WHEREAS, **US WORLDMEDS, LLC**, a Delaware limited liability company (the "Grantor") and Secured Party are parties to a certain Amended and Restated Pledge and Security Agreement dated as of September 20, 2012 (the "Security Agreement"); and

WHEREAS, reference is made to those certain Notices of Security Interest dated as of September 20, 2012 and March 16, 2015 by Grantor in favor of Secured Party (the "Notices"); and

WHEREAS, pursuant to the Security Agreement and Notices, the Grantor granted to the Secured Party a security interest in certain of the Grantor's assets, including, without limitation, the Copyrights, Patents, and Trademarks as defined in the Security Agreement owned by Grantor (collectively, the "Intellectual Property"), including the Intellectual Property listed on Schedule A to the Notice; and


WHEREAS, the Notices were recorded with the trademark division of the United States Patent and Trademark Office on September 25, 2012 at Reel/Frame 4866/0683 and on April 9, 2015 at Reel/Frame 5495/0412 and with the patent division of the United States Patent and Trademark Office on September 25, 2012 at Reel/Frame 029033/0301;

NOW, THEREFORE, intending to be legally bound hereby and in connection with the Security Agreement, Secured Party hereby releases and remits, without any recourse, representation or warranty, any and all rights, title and interests in and to the Intellectual Property, including, without limitation, the Intellectual Property set forth on Schedule A attached hereto, and hereby authorizes the Grantor or Grantor's authorized representative to record this Release with the United States Patent and Trademark Office as evidence of such release.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Secured Party duly executes this Release, which is effective as of the day and year first written above.

JPMORGAN CHASE BANK, N.A.,
as Secured Party

By: 
Name: Timothy W. Kennedy
Title: Authorized Signer

{Signature Page to Release of Security Interest (US WorldMeds)}

SCHEDULE A**PATENTS**UNITED STATES

TITLE	SERIAL NO.	FILED	REG. NO.	REG. DATE
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	12205303	9/5/08	8975284	3/10/15
Compositions and methods for transmucosal delivery of lofexidine	12410114	3/24/09		
Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery	12999659	12/17/10		
Intranasal delivery system for dantrolene	13266358	10/26/11		
Transdermal delivery of apomorphine using microneedles	13060118	2/22/11		

FOREIGN

TITLE	COUNTRY/ JURISDICTION	REG. NO./APP. NO.
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	Canada	2702243
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	European Patent Convention	088370796
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	Japan	2010-528917
Composition and method for transmucosal delivery of lofexidine	European	097246508
Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery	European	097710099
Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery	European	110022241
Transdermal delivery of apomorphine using microneedles	European	0980887011217

TRADEMARKS

UNITED STATES

MARK	SERIAL NO.	FILED	REG. NO.	REG. DATE
REVONTO	77880100	11/24/09	3871489	11/2/10
APOKYN	78269572	7/2/03	2973482	7/19/05

FOREIGN

MARK	COUNTRY/ JURISDICTION	REG. NO./APP. NO.
MYOBLOC	Canada	TMA809909
MYOBLOC	Republic of Korea	40-0783616
NERBLOC (Roman and Katakana)	Japan	4983424
NEUROBLOC	Benelux	782785
NEUROBLOC	Canada	TMA516043
NEUROBLOC	European Community	611384
NEUROBLOC	Iceland	6752000
NEUROBLOC	Norway	203409
NEUROBLOC	Switzerland	476705
NEUROBLOC	Turkey	2002009753
REVONTO	European Community	009008137
SOLSTICENEURO	Benelux	781112